Magazine Article | April 6, 2018

Reata Pharmaceuticals: Return & Reach Beyond

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

The Enterprisers: Life Science Leadership In Action

What good can come of setback? What is the value, if any, in so-called failure? Must a “failed” clinical trial wind up in the great waste bin of misbegotten science? Actually, history answers those questions unequivocally. Setbacks can lead to new opportunities. Failure can clarify the goals, direction, and mission of the project. Trials that fail to verify the original hypothesis can light a better path to the truth. That is why merely dividing total R&D spending by successful drug approvals does not yield a real solution — one that accounts for the full value of biopharma research and development. If there were a price tag on new information or knowledge — a negative cost, so to speak — the equation would rebalance, adding value to that of new products at the macro, industry scale.

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader